Identification of Key Genes and Signaling Pathways Associated with the Progression of Glioblastoma multiform

Vastrad, Basavaraj; Vastrad, Chanabasayya; Kotturshetti, Iranna

doi:10.1101/2020.12.21.20248616

Cited by 2 publications

(1 citation statement)

References 231 publications

(233 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other RPs are commonly overexpressed in GB tumors, including RPS11, RPS20, RPL5, and RPS27 ( Yong et al, 2015 ; Fancello et al, 2017 ; Feldheim et al, 2020a ; Vastrad et al, 2020 ). The involvement of different RP in the GB biology is summarized in Table 2 and Figure 5 .…”

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

The dark side of mRNA translation and the translation machinery in glioblastoma

Montiel-Dávalos

Ayala²,

Hernández³

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Among the different types of cancer affecting the central nervous system (CNS), glioblastoma (GB) is classified by the World Health Organization (WHO) as the most common and aggressive CNS cancer in adults. GB incidence is more frequent among persons aged 45–55 years old. GB treatments are based on tumor resection, radiation, and chemotherapies. The current development of novel molecular biomarkers (MB) has led to a more accurate prediction of GB progression. Moreover, clinical, epidemiological, and experimental studies have established genetic variants consistently associated with the risk of suffering GB. However, despite the advances in these fields, the survival expectancy of GB patients is still shorter than 2 years. Thus, fundamental processes inducing tumor onset and progression remain to be elucidated. In recent years, mRNA translation has been in the spotlight, as its dysregulation is emerging as a key cause of GB. In particular, the initiation phase of translation is most involved in this process. Among the crucial events, the machinery performing this phase undergoes a reconfiguration under the hypoxic conditions in the tumor microenvironment. In addition, ribosomal proteins (RPs) have been reported to play translation-independent roles in GB development. This review focuses on the research elucidating the tight relationship between translation initiation, the translation machinery, and GB. We also summarize the state-of-the-art drugs targeting the translation machinery to improve patients’ survival. Overall, the recent advances in this field are shedding new light on the dark side of translation in GB.

show abstract

Section: Translation and Gb In The Spotlightmentioning

confidence: 99%

The dark side of mRNA translation and the translation machinery in glioblastoma

Montiel-Dávalos

Ayala²,

Hernández³

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel

Ahmed,

Semreen,

Giddey

et al. 2023

Annals of Medicine

View full text Add to dashboard Cite

Background Glioblastoma (GBM) is a primary malignancy of the central nervous system and is classified as a grade IV astrocytoma by the World Health Organization (WHO). Although GBM rarely metastasizes, its prognosis remains poor. Moreover, the standard treatment for GBM, temozolomide (TMZ), is associated with chemoresistance, which is a major factor behind GBM-related deaths. Investigating drugs with repurposing potential in the context of GBM is worthwhile to bypass lengthy bench-to-bedside research. The field of omics has garnered significant interest in scientific research because of its potential to delineate the intricate regulatory network underlying tumor development. In particular, proteomic and metabolomic analyses are powerful approaches for the investigation of metabolic enzymes and intermediate metabolites since they represent the functional end of the cancer phenotype. Methods We chose two of the most widely prescribed anticancer drugs, cisplatin and paclitaxel. To our knowledge, the current literature lacks studies examining their effects on metabolic and proteomic alterations in GBM. We employed the mass spectrometry technological platform ‘UHPLC-Q-TOF-MS/MS’ to examine the changes in the proteome and metabolome profiles of the U87 cell line with defined concentrations of cisplatin and/or paclitaxel via an untargeted approach. Results A total of 1,419 distinct proteins and 90 metabolites were generated, and subsequent analysis was performed. We observed that upon treatment with cisplatin (9.5 μM), U87 cells exhibited apparent efforts to cope with this exogenous stressor, understanding the effect of paclitaxel (5.3 μM) on altering the transport machinery of the cell, and how the combination of cisplatin and/or paclitaxel suggests potential interactions with promising benefits in GBM therapeutics. Conclusion Our research provides a detailed map of alterations in response to cisplatin and paclitaxel treatment, provides crucial insights into the molecular basis of their action, and paves the way for further research to identify molecular targets for this elusive malignancy.

show abstract

Identification of Key Genes and Signaling Pathways Associated with the Progression of Glioblastoma multiform

Cited by 2 publications

References 231 publications

The dark side of mRNA translation and the translation machinery in glioblastoma

The dark side of mRNA translation and the translation machinery in glioblastoma

Proteomic and metabolomic signatures of U87 glioblastoma cells treated with cisplatin and/or paclitaxel

Contact Info

Product

Resources

About